Tarsus Pharmaceuticals (TARS) Stock Statistics & Valuation Metrics

Tarsus Pharmaceuticals has a market cap or net worth of $1.91B. The enterprise value is $1.92B.

Tarsus Pharmaceuticals has 41.61M shares outstanding. The number of shares has decreased by -2.65% in one year.

Tarsus Pharmaceuticals’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -40.60%.

The current PE Ratio of Tarsus Pharmaceuticals is -18.02. Tarsus Pharmaceuticals’s PEG ratio is 0.54.

In the last 12 months, Tarsus Pharmaceuticals had revenue of $182.95M and earned -$115.55M in profits. Earnings per share was -$3.11.

In the last 12 months, operating cash flow was -$83.03M and capital expenditures -$6.57M, giving a free cash flow of -$89.59M billion.

Tarsus Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of

Tarsus Pharmaceuticals upcoming earnings date is May 13, 2025, After Close.

Tarsus Pharmaceuticals as a current ratio of 4.42, with Debt / Equity ratio of 0.32

In the past 12 months, Tarsus Pharmaceuticals has paid -$270.00K in taxes.

Tarsus Pharmaceuticals EV to EBITDA ratio is -19.27, with an EV/FCF ratio of -24.35.

Tarsus Pharmaceuticals has $291.38M in cash and marketable securities with $72.45M in debt, giving a net cash position of -$218.92M billion.

Gross margin is 92.99%, with operating margin of -65.90%, and net profit margin of -63.16%.

The average price target for Tarsus Pharmaceuticals is $67.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy